Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center Phase 2 clinical trial in newly diagnosed infants with X-linked severe combined immunodeficiency (XSCID) between two months to two years of age

Trial Profile

A multi-center Phase 2 clinical trial in newly diagnosed infants with X-linked severe combined immunodeficiency (XSCID) between two months to two years of age

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 19 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MB 107 (Primary)
  • Indications Immunodeficiency disorders; X-linked genetic disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors Mustang Bio

Most Recent Events

  • 11 Aug 2022 According to a Mustang Bio media release, In 2023, the company expect to enroll the first patient in a pivotal multicenter Phase 2 clinical trial under Mustang Bio's Investigational New Product Drug Application (IND) to evaluate MB-107, a lentiviral gene therapy for the treatment of infants under the age of two with XSCID.
  • 17 May 2021 According to Fortress Biotec media release, top-line data from this trial is expected in the second half of 2022.
  • 02 Feb 2021 According to a Mustang Bio media release, the company plans to submit to enroll first patient in this trial in the second quarter of 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top